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Abstract
AIM
To describe the frequency and clinical characteristics of 
patients with undifferentiated periodic fever (UPF) and to 
investigate whether a clinical classification of UPF based 
on the PRINTO-Eurofever score can help predicting the 
response to treatment and the outcome at follow-up.
METHODS
Clinical and therapeutic information of patients with 
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recurrent fever who presented at a single pediatric rheu-
matology center from January 2006 through April 
2016 were retrospectively collected. Patients with a 
clinical suspicion of hereditary periodic fever (HPF) 
syndrome and patients with clinical picture of periodic 
fever, aphthae, pharingitis, adenitis (PFAPA) who were 
refractory to tonsillectomy underwent molecular analysis 
of five HPF-related genes: MEFV (NM_000243.2), MVK 
(NM_000431.3), TNFRSF1A  (NM_001065.3), NLRP3 
(NM_001079821.2), NLRP12  (NM_001277126.1). All 
patients who had a negative genetic result were defined 
as UPF and further investigated. PRINTO-Eurofever 
score for clinical diagnosis of HPF was calculated in all 
cases. 
RESULTS
Of the 221 patients evaluated for periodic fever, 
twelve subjects with a clinical picture of PFAPA who 
were refractory to tonsillectomy and 22 subjects with 
a clinical suspicion of HPF underwent genetic analysis. 
Twenty-three patients (10.4%) resulted negative and 
were classified as UPF. The median age at presentation 
of patients with UPF was 9.5 mo (IQR 4-24). Patients 
with UPF had a higher frequency of aphthae (52.2% 
vs  0%, P  = 0.0026) and musculoskeletal pain (65.2% 
vs  18.2%, P  = 0.0255) than patients with genetic 
confirmed HPF. Also, patients with UPF had a higher 
frequency of aphthous stomatitis (52.2% vs  10.7%, P  
< 0.0001), musculoskeletal pain (65.2% vs  8,0%, P  
< 0.0001), and abdominal pain (52.2% vs  4.8%, P  < 
0.0001) and a lower frequency of pharyngitis (56.6% 
vs  81.3%, P  = 0.0127) compared with typical PFAPA in 
the same cohort. Twenty-one of 23 patients with UPF 
(91.3%) received steroids, being effective in 16; 13 
(56.2%) were given colchicine, which was effective in 6. 
Symptoms resolution occurred in 2 patients with UPF at 
last follow-up. Classification according to the PRINTO-
Eurofever score did not correlate with treatment re-
sponse and prognosis. 
CONCLUSION
UPF is not a rare diagnosis among patients with periodic 
fever. Clinical presentation place UPF half way on a 
clinical spectrum between PFAPA and HPF. The PRINTO-
Eurofever score is not useful to predict clinical outcome 
and treatment response in these patients.
Key words: Hereditary periodic fever syndromes; Therapy; 
Genetics; Autoinflammatory diseases; Undifferentiated 
periodic fever
© The Author(s) 2018. Published by Baishideng Publishing 
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Core tip: Children with non-infectious recurrent fever 
more often fall into two diagnostic categories. The 
first and most common is periodic fever, aphthae, 
pharingitis, adenitis (PFAPA), the second, far more rare, 
are hereditary periodic fevers. Very recently a third 
category has been increasingly recognized, and is that 
of undifferentiated periodic fevers or undifferentiated 
periodic fever (UPF). UPF include patients who do not 
meet the diagnostic criteria for PFAFA or for a monogenic 
disease. The clinical presentation and management of 
patients with UPF are poorly defined. In this study, the 
authors describe a cohort of patients with UPF showing 
that: (1) The clinical manifestations are on a half way of 
clinical spectrum between PFAPA and hereditary periodic 
fever; (2) PRINTO-Eurofever score is not useful to guide 
treatment choices and does not predict disease course; 
and (3) Both steroids and colchicine are useful to 
control symptoms in most cases. The authors conclude 
that further studies are needed to better define UPF and 
guide their management in clinical practice.
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INTRODUCTION
Periodic fever is defined as recurrences of seemingly 
unprovoked episodes of fever that last from a few days 
to a few weeks, separated by symptom-free intervals of 
variable duration[1].
The most common cause of periodic fever syndrome 
in children is PFAPA (periodic fever, aphthae, pharingitis, 
adenitis), an autoinflammatory condition[2] characterized 
by recurrence of fever associated with aphthous sto-
matitis, pharyngitis, and/or cervical adenopathy. The 
diagnosis of PFAPA is based on Thomas criteria: recurring 
fevers that begin before age 5 and are accompanied 
by at least one of the clinical signs aphthous stomatitis, 
pharyngitis or adenitis, without upper respiratory infec-
tion[3]. The pathogenesis of PFAPA is likely multifactorial, 
but evidence of familial recurrence of this syndrome may 
support a genetic predisposition. Patient with PFAPA 
respond to steroids[2] and heal spontaneously, usually in 
few years, or after tonsillectomy without sequelae[4,5]. Lack 
of response to tonsillectomy in PFAPA is uncommon and 
should raise the suspicion of a monogenic condition[6,7]. 
Other rarer periodic fever syndromes are due to 
definite monogenic defects involving mechanisms of 
inflammation (hereditary periodic fevers - HPF). The first 
described was familial mediterranean fever (FMF) which 
has been linked to MEFV gene in late nighties. Afterwards, 
a number of HPF syndromes have been described, and 
their genetic bases has been provided. This is the case 
for example of: tumor necrosis factor receptor-associated 
periodic syndrome (TRAPS), associated with TNFRSF1A 
gene defects, hyperimmunoglobulinemia D with periodic 
fever syndrome (HIDS), related to MVK gene, and 
cryopyrin-associated periodic syndromes (CAPS) for 
which defects on either NLRP3 or NLRP12 have been 
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identified[8,9].
Timely diagnosis of HPF is essential since effective 
therapies are now available, and complications, such 
as amyloidosis and sensor neural impairment, can be 
avoided[10].
The term undifferentiated periodic fever (UPF) has 
been increasingly used to define those patients pre-
senting with a complaint of periodic fever in whom the 
diagnostic criteria for PFAPA are not satisfied and genetic 
work-up for periodic fever gives a negative result.
On a practical ground, subjects with PFAPA who are 
refractory to tonsillectomy and/or to steroids may be as 
well included in the group of UPF.
Even though patients with UPF are increasingly re-
cognized in clinical practice, the only epidemiologic data 
available comes from the Eurofever Registry were, 
in 2014, patients with an “undefined periodic fever” 
accounted for almost 9% of cases[11]. 
The management of such patients is challenging, 
as clinical manifestations are poorly described and the 
prognosis and response to treatment are unknown. 
Federici et al[12] recently validated a score for clinical 
classification of patients with periodic fever into the main 
four phenotypes of HPF (PRINTO-Eurofever score), and 
proposed that it could be used to classify patients with 
periodic fever in daily practice. The score considers age 
at disease onset, ethnicity and the presence or absence 
of specific clinical symptoms. 
With the present study, we aimed to describe the 
frequency and clinical characteristics of patients with a 
diagnosis of UPF. Moreover, we calculated the PRINTO-
Eurofever score in subjects with UPF to investigate if a 
clinical classification in HPF-like phenotypes (clinical score 
of HPF in the absence of genetic confirmation) could help 
predicting the response to treatment and prognosis.
MATERIALS AND METHODS
Patients
This was a retrospective cohort study conducted at a 
single Rheumatology Center caring for pediatric patients 
with rheumatologic and autoinflammatory conditions. 
The Study was approved by the local Ethics Committee. 
Clinical charts of patients who received a diagnosis of 
periodic fever during a ten-year period, from January 
2006 through April 2016, were reviewed. Patients older 
than 18 years at the time of data collection were not 
included as they were no more referred to our Institute. 
Criteria
All the patients with periodic fever were included in 
the study. Subjects with a clinical suspicion of HPF and 
subjects with a suspicion of PFAPA (Thomas’s criteria) 
who didn’t respond to steroid treatment or had a 
recurrence of symptoms after tonsillectomy underwent 
genetic analysis for five genes mostly involved in HPF, 
namely: MEFV (NM_000243.2) for familial mediterranean 
fever (FMF), MVK (NM_000431.3) for mevalonate kinase 
deficiency (MKD), TNFRSF1A (NM_001065.3) for TNFα 
receptor associated periodic syndrome (TRAPS), NLRP3 
(NM_001079821.2) and NLRP12 (NM_001277126.1) 
for familial cold urticaria syndrome. Patients with 
known causative mutation were diagnosed with the 
corresponding disorder. 
Subjects with negative results or polymorphisms 
of unknown significance were considered as UPF[13], 
irrespective of whether they came from the group of 
PFAPA who were refractory to tonsillectomy or patients 
suspected with HPF. This choice was based on the 
consideration that both subjects with a clinical suspicion 
of HPF and subjects with a suspicion of PFAPA, refractory 
to tonsillectomy or to steroids, share the same problems 
as concerns the lack of a definite prognosis and of a 
therapeutic approach.
Thus, three groups of subjects were finally identified 
based on clinical and genetical features: Typical PFAPA, 
genetically confirmed HPF, UPF. 
Data collection
Data collected included information on: gender, family 
history, ethnicity, duration of fever episodes, presence 
of pharyngitis, adenitis or aphthae, presence of 
musculoskeletal, chest or abdominal pain, diarrhea, 
vomiting, skin rash, conjunctivitis, and sensory neural 
hearing loss. Data were collected at disease onset 
and during follow-up. PRINTO-Eurofever score was 
calculated retrospectively at last follow-up[12]. Based on 
PRINTO-Eurofever score, patients who scored positive 
were assigned to a specific HPF phenotype according 
to the same scoring system. A possible relationship 
between the clinical diagnosis based on PRINTO-
Eurofever criteria and response to treatment at follow 
up was assessed.
Statistical analysis
Statistical analysis were made using GraphPad Prism 
5 software. Categorical variables were summarized as 
frequency and percentage and were compared across 
independent groups by the Fisher’s exact test (two 
tailed, confidence interval 95%). Numerical variables 
with asymmetrical distribution were summarized 
by median and interquartile range (IQR) and were 
compared by the Kruskal-Wallis test. A P value < 0.05 
was considered for significance.
RESULTS
During a ten-year period, 221 patients were evaluated 
for periodic fever. Twenty-two patients had a suspicion 
of HPF and a definite diagnosis could be genetically 
confirmed in 11 of them (5 MKD, 3 TRAPS, 2 FMF, 1 
FCU). The other 11 subjects resulted negative and were 
considered as UPF. 
PFAPA was suspected in 199 subjects, 12 of whom 
did not respond to steroids or persisted after tonsil-
lectomy and underwent genetic analysis. None of these 
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subjects had causative mutations of HPF genes. In 6 
patients, variants of unknown significance were found. 
Four patients had heterozygous mutations of which two 
were in the MEFV gene (P369S-R408Q and V726A), one 
in the MVK gene (V377I) and one in NLRP12 (variation 
H304Y). Two patients had a homozygous R202Q variant 
in MEFV. Thus, all 12 subjects were considered as UPF. 
Overall, a total of 23 patients (10%) met the diagnosis 
of UPF and where thus included in the analysis. UPF 
Cohort selection is reported in Figure 1.
Baseline characteristics of patients with UPF and 
comparison with HPF and PFAPA
Baseline demographic and clinical characteristics of 
patients are described in Table 1. 
The most frequent complaints at first visit in UPF 
were exudative pharyngitis (13 patients, 56.6%), 
musculoskeletal pain (15 pt, 65.2%), aphthous stomatitis 
(12 pt, 52.2%) and abdominal pain (12 pt, 52.2%). No 
patient suffered from chest pain. Abdominal pain in the 
UPF group was reported as mild to moderate and never 
led to an evaluation for acute abdomen. 
Median duration of disease at last follow-up was 
6.3 years (IQR 0.9-17.8 year). Median follow-up since 
inclusion in the study was 3.3 years (IQR 0.3-9.4 year).
Subjects with UPF had a similar age at disease onset 
compared with HPH (P = 0.9), while they had an earlier 
onset compared with PFAPA (P = 0.008).
Compared with HPF, patients with UPF were more 
likely to have aphthae (52.2% vs 0%, P = 0.0026) and 
musculoskeletal pain (65.2% vs 18.2%, P = 0.0255), 
while compared with PFAPA they were more likely 
to have aphthous stomatitis (52.2% vs 10.7%, P < 
0.0001), musculoskeletal pain (65.2% vs 8.0%, P < 
0.0001), abdominal pain (52.2% vs 4.8%, P < 0.0001) 
but were less likely to have pharyngitis (56.6% vs 
81.3%, P = 0.0127).
Therapeutic strategies received at any time and 
response to therapy in UPF
An oral glucocorticoid (betamethasone) was the first 
therapeutic choice in 21/23 patients. In 16 patients 
(69.5%), oral administration of betamethasone deter-
mined immediate resolution of the acute episode; in 11 
patients, a standard dose of 0.1 mg/kg of betamethasone 
was effective, in 5 higher doses of 0.2-0.3 mg/kg were 
required. In 8 patients, who came from the group with 
initial suspicion of PFAPA, acute episodes became more 
frequent after glucocorticoid treatment. Tonsillectomy was 
performed in 12 patients being ineffective in all of them. 
Thirteen patients were treated with daily oral 
colchicine (0.5-1.5 mg/die), which reduced or abated 
symptoms recurrence in 6 patients (46%). All patients 
receiving colchicine had been previously treated with 
steroids. The reason for switching to colchicine was 
steroids being ineffective in 3 patients, and need for too 
high or too frequent corticosteroid doses in 10 patients.
At last follow-up, 21/23 (91%) were still receiving 
medical treatment for the management of acute 
symptoms: 10 patients received corticosteroids during 
acute episodes; 7 patients were on daily colchicine and 
4 patients were receiving non-steroidal antinflammatory 
drugs (NSAID); 2 patients healed spontaneously.
Classification of patients based on PRINTO-Eurofever 
score at baseline and response to therapy
At baseline, 11 subjects could be classified as HPF-like: 
3 patients had a positive score for FMF, 5 for MKD, 3 for 
Table 1  Baseline characteristics and symptoms distribution of patients with periodic fever in our cohort
Undifferentiated periodic fever (n  = 23) PFAPA (n  = 187) HPF (n  = 11)
Females, n (%) 18 (70%) 74 (38%) 7 (63%)
Ethnicity, n 
  EU 20 183 11
  Arabian   2     2   0
  Mix   1     2   0
Median age at onset, mo (IQR) 9.5 (4-24) 12.5 (2.5-96) 9 (1-174)
Median age at first visit, mo (IQR) 51 (33-113) 42.15 (8-120) 48 (12-216)
Symptoms, n (%)
  Pharyngitis 13 (56.6%) 152 (81.3%) 4 (36.3%)
  Aphtae 12 (52.2%) 20 (10.7%) 0 (0%)
  Chest pain 0 (0%) 0 (0%) 1 (9%)
  Abdominal pain 12 (52.2%) 9 (4.8%) 6 (54.5%)
  Musculoskeletal pain 15 (65.2%) 15 (8.0 %) 2 (18.2%)
12 no response
 to tonsillectomy
187 confirmed 
PFAPA
11 negative
 genetic results
11 HPF 
confirmed
22 suspected 
HPF
221 patients
23 UPF
Figure 1  Selection of undifferentiated periodic fever cohort. PFAPA: 
Periodic fever, aphthae, pharingitis, adenitis; HPF: Hereditary periodic fever; 
UPF: Undifferentiated periodic fever.
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TRAPS, 1 for CAPS (1 patient was positive for FMF and 
MKD). Twelve patients had negative scores for HPF. 
We didn’t observe a clear relationship between 
PRINTO-Eurofever score at baseline and response to 
treatment received at any time. In particular, no patient 
who responded to colchicine had a clinical score suppor-
tive of FMF. As opposite, 2 out of 7 patients who did not 
respond to colchicine had a positive score for FMF.
DISCUSSION
In a single pediatric rheumatology center, 10% of 
patients presenting with a complaint of periodic fever 
could be classified as UPF. Even if PFAPA was by far 
the most frequent diagnosis, UPF was a more common 
diagnosis compared to HPF.
Age at symptoms presentation patients with UPF was 
quite varied, ranging from 2 to 111 mo. Interestingly, 
the median age at disease onset in of UPF was closer 
to that of HPF than that of PFAPA, similarly to what has 
been reported in the literature[11], suggesting the possi-
bility of a stronger contribution of genetic factors in UPF 
compared with PFAPA.
Musculoskeletal pain and recurrent pharyngitis were 
the most frequent complaints followed by recurrence 
of aphthous stomatitis and abdominal pain. The high 
frequency of pharyngitis and stomatitis reflects the 
fact that the majority of patients classified as UPF had 
been initially diagnosed as PFAPA. It should be noted, 
however, that all these patients had a more complex 
phenotype compared to patients with a definitive diagnosis 
of PFAPA, as most of them complained of musculoskeletal 
or abdominal pain, in addition to pharyngitis.
The frequency of abdominal pain alone was similar 
in UPF and HPF, and in both cases it was significantly 
higher than in PFAPA. Notably, chest pain was never 
reported in patients with UPF.
According to these observations, UPF seem to be 
half way on a clinical spectrum of disease severity 
ranging from PFAPA to HPF. Patients with UPF in fact had 
more frequent “extrapharingeal” symptoms, namely 
musculoskeletal and abdominal pain, compared to PFAPA 
but despite their frequency, these symptoms were never 
as severe as those reported in HPF.
Overall, steroids were an effective strategy to control 
symptoms in a high proportion of patients.
For patients who needed steroids at high doses or 
frequency, daily oral colchicine was a useful alternative 
strategy to control symptom recurrence.
Tonsillectomy did not resolve fever recurrence in UPF 
patients, but this observation is biased, as this was one 
of the criteria that we chose for patients’ inclusion in the 
UPF group.
We evaluated if a clinical classification of our cases 
could have been used to predict the response to therapy. 
So far, the only suitable classification proposed for 
subjects with periodic fever syndromes is the PRINTO-
Eurofever score, which was developed to help experts 
classifying patients with suspected autoinflammatory 
fever syndromes without relying on genetic analyses. 
The score was calculated based on clinical features 
selected on a multivariate analysis on a large group of 
patients with different periodic fevers[12]. 
We showed that PRINTO-Eurofever classification at 
baseline could not predict response to any treatment. 
Thus, even though the short time to last follow up 
for some patients, PRINTO-Eurofever score at baseline 
seems not to be predictive of symptoms persistence over 
time.
Several limitations of the study are acknowledged. 
Due to its retrospective design, clinical data were not 
systematically collected. The sample size is small, and 
recruitment occurred at one Tertiary-referral Clinic 
thus limiting the generalizability of our observation. 
Moreover, the median time to follow-up was too short 
to estimate long-term prognosis. In fact, considering 
that a significant proportion of UPF showed both recurrent 
aphthous ulcers and abdominal or musculoskeletal pain, 
it is still possible that part of them will develop a Behcet 
disease (BD) on a longer follow-up. Indeed, Cantarini 
et al[14] recently showed that many subjects with adult 
BD complained of periodic fever and aphthae during 
Table 2  Treatment response in undifferentiated periodic fever cohort as a whole and in undifferentiated periodic fever subgroups 
according to PRINTO-Eurofever classification at baseline1
Undifferentiated periodic fever (n  = 23) Positive score (n  = 11) Negative score (n  = 12)
Glucocorticoids
  Total 21 11 12
  Responsive 16   9 10
  Not responsive   5   2   2
Colchicine
  Total 13   6   7
  Responsive   6   4   2
  Not responsive   7   2   5
Tonsillectomy
  Total 12   5   7
  Responsive   0   0   0
  Not responsive 12   5   7
1Statistical significance could not be calculated, due to the small size of the sample.
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childhood. Moreover, we cannot exclude that some patient 
with UPF could have a different monogenic disorder, but 
this seem unlikely at present, given that increasing the 
number of candidate genes in genetic panels did not 
result in increased diagnoses[15].
In conclusion, according to our observation patients 
with UPF seem not to be rare in clinical practice. Clinical 
presentation places them half way on a clinical spectrum 
between PFAPA and HPF. Classification of patients with 
UPF into a specific HPF phenotype according PRINTO-
Eurofever criteria is not useful to guide treatment choice 
and does not predict disease prognosis. Given the above-
mentioned limitation, what we observed represent and 
initial attempt to describe a poorly defined subset of 
patients with periodic fever commonly encountered in 
clinical practice. Further studies are needed to better 
define patients with UPF and guide their management in 
clinical practice.
ARTICLE HIGHLIGHTS
Research background
Undifferentiated periodic fevers (UPF) include periodic fever not meeting the 
diagnostic criteria for typical PFAPA of for hereditary periodic fever syndromes. 
Even if UPF are increasingly recognized, there is currently no recommendation 
to guide the management of children with this condition. 
Research motivation
Clinical criteria to classify periodic fever without the help of genetic analyses 
have been proposed by PRINTO Eurofever, and might be particularly useful 
for subjects with UPF. Thus, we studied the clinical features of our patients in 
relation with their scores in the PRINTO-Eurofever classification. 
Research objectives 
Our study aims at improving knowledge on UPF and at evaluating if the 
application of the PRINTO-Eurofever classification can help the clinical 
management of these patients. 
Research methods
A data base was filled in by retrospective review of clinical records, follow-up 
visits and phone calls. A structured questionnaire was used to classify all the 
subjects with the PRINTO-Eurofever score. The response to therapies and the 
prognosis at follow-up was compared with the clinical diagnosis obtained with 
the PRINTO-Eurofever score.
Research results
The clinical manifestations are on a half way of clinical spectrum between 
PFAPA and hereditary periodic fever. PRINTO-Eurofever score is not useful to 
guide treatment choices and does not predict disease course. Both steroids and 
colchicine are useful to control symptoms in most cases.
Research conclusions
UPF are as common as hereditary periodic fever, however knowledge on 
prognosis and response to therapies in these patients is lacking. 
Research perspectives
Multicenter studies and experts’ agreement are needed to develop recom-
mendations for the management of UPF.
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